Trial reportCancer2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
Trial report in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 132 citations in OpenAlex.
- The Impact of Monosodium Glutamate onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Trial
- A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti-PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Influence of increased injected activities up 9.0 GBq [EJNMMI physics · 2026Article
- Theranostic Potential ofCancers · 2026Article
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Fractionation gives therapeutic benefit in animal model of [EJNMMI research · 2026Article
- Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy.Theranostics · 2026Article
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Clinical perspective on targeted alpha therapy usingAnnals of nuclear medicine · 2025Review
- [PSMA radioligand therapy-State of the art].Urologie (Heidelberg, Germany) · 2025Review
- Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody.Molecular imaging and biology · 2025Article
- Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide Therapy.Molecular pharmaceutics · 2025Article
- A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma.Scientific reports · 2025Article
- Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.Molecular cancer therapeutics · 2025Article
- A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer.NPJ precision oncology · 2025Article
- Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.Frontiers in oncology · 2025Review
- Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors.Frontiers in immunology · 2025Review
- Current landscape and clinical progress of targeted alpha radioimmunotherapy.American journal of nuclear medicine and molecular imaging · 2025Review
- Targeted and immunotherapeutic strategies for castration-resistant prostate cancer: emerging strategies, challenges, and future directions.Frontiers in immunology · 2025Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundProstate cancer is radiosensitive. Prostate-specific membrane antigen (PSMA) is selectively overexpressed on advanced, castration-resistant tumors. Lutetium-177-labeled anti-PSMA monoclonal antibody J591 (
methodMen with metastatic castration-resistant prostate cancer refractory to or refusing standard treatment options with normal neutrophil and platelet counts were enrolled in initial phase 1b dose-escalation cohorts followed by phase 2a cohorts treated at recommended phase 2 doses (RP2Ds) comprising 2 fractionated doses of
resultsForty-nine men received fractionated doses of
conclusionFractionated administration of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.